From CO2 to Er:YAG: A Comprehensive Review of Laser Treatments for Rhinophyma.

IF 1.5 4区医学 Q3 DERMATOLOGY Journal of Drugs in Dermatology Pub Date : 2024-11-01 DOI:10.36849/JDD.8199

Payvand Kamrani, Monica Boen, Sabrina G Fabi, Mitchel P Goldman

{"title":"From CO2 to Er:YAG: A Comprehensive Review of Laser Treatments for Rhinophyma.","authors":"Payvand Kamrani, Monica Boen, Sabrina G Fabi, Mitchel P Goldman","doi":"10.36849/JDD.8199","DOIUrl":null,"url":null,"abstract":"Background: Rhinophyma, a benign condition resulting in nasal sebaceous tissue hypertrophy, predominantly affects Caucasian males. There are numerous surgical and medical treatments for rhinophyma with varying degrees of success. This review aims to provide a comprehensive overview of ablative therapies, highlighting our preferred treatment approach.Methods: This review analyzes the evidence behind ablative lasers in treating rhinophyma, with a focus on the 10600 nm carbon dioxide (CO2) and 2940 nm erbium: yttrium-aluminum-garnet (Er:YAG).Results: Both CO2 and Er:YAG have demonstrated efficacy in treating rhinophyma. CO2 laser ablation results in a higher incidence of scarring and hypopigmentation. Er:YAG has high water absorption, which results in less thermal damage, allowing for quicker healing and fewer complications.Conclusion: Management of rhinophyma can remain challenging; however, ablative lasers are an effective treatment. Both laser types have promising outcomes, each with different advantages and complications. In particular, Er:YAG presents fewer complications compared to CO2 lasers. J Drugs Dermatol. 2024;23(11):932-936. doi:10.36849/JDD.8199.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Rhinophyma, a benign condition resulting in nasal sebaceous tissue hypertrophy, predominantly affects Caucasian males. There are numerous surgical and medical treatments for rhinophyma with varying degrees of success. This review aims to provide a comprehensive overview of ablative therapies, highlighting our preferred treatment approach.

Methods: This review analyzes the evidence behind ablative lasers in treating rhinophyma, with a focus on the 10600 nm carbon dioxide (CO2) and 2940 nm erbium: yttrium-aluminum-garnet (Er:YAG).

Results: Both CO2 and Er:YAG have demonstrated efficacy in treating rhinophyma. CO2 laser ablation results in a higher incidence of scarring and hypopigmentation. Er:YAG has high water absorption, which results in less thermal damage, allowing for quicker healing and fewer complications.

Conclusion: Management of rhinophyma can remain challenging; however, ablative lasers are an effective treatment. Both laser types have promising outcomes, each with different advantages and complications. In particular, Er:YAG presents fewer complications compared to CO2 lasers. J Drugs Dermatol. 2024;23(11):932-936. doi:10.36849/JDD.8199.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

从 CO2 到 Er:YAG：鼻叶斑激光疗法综合评述。

背景：鼻赘是一种导致鼻腔皮脂腺组织肥大的良性疾病，主要影响白种男性。目前有许多手术和药物治疗鼻赘的方法，但成功率各不相同。本综述旨在全面概述消融疗法，重点介绍我们首选的治疗方法：本综述分析了烧蚀激光治疗鼻赘的证据，重点是 10600 纳米二氧化碳（CO2）和 2940 纳米铒：钇铝石榴石（Er:YAG）：结果：二氧化碳激光和 Er:YAG 激光在治疗鼻息肉方面都有显著疗效。CO2 激光消融会导致较高的瘢痕和色素沉着发生率。Er:YAG 具有较高的吸水性，热损伤较小，因此愈合更快，并发症更少：结论：鼻大疱的治疗仍具有挑战性，但烧蚀激光是一种有效的治疗方法。两种激光类型都有良好的疗效，但各有不同的优点和并发症。尤其是 Er:YAG 激光与 CO2 激光相比，并发症更少。J Drugs Dermatol.2024;23(11):932-936. doi:10.36849/JDD.8199.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.